European School of Oncology First Euro-American Forum on Lung Cancer Treatment

Bunn, Paul A.; Zandwijk, Nico van; Pastorino, Ugo; Aisner, Joseph; Alberto, P.; Arriagada, R.; Carney, Desmond N.; Cornis, R.; Dittrich, Ch.; Gatzemeier, U.; Ginsberg, Robert J.; Greco, F. Anthony; Hansen, H.H.; Harper, Peter; Henriksson, Roger; H, Huber; Klener, P; Lechevalier, T.; Lewensohn, Rolf; Murray, Nevin; Niederle, N.; Postmus, Pieter E.; Rosell, R.; Scagliotti, Giorgio V.; Sculier, Jean-Paul; Splinter, Ted A.W.; Stahel, Rolf A.; Symann, Michel; Thatcher, Nick; Tonato, Maurizio; Turrisi, Andrew T.

doi:10.1016/0959-8049(94)90551-7

Cited by 18 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival of non-small-cell carcinoma is closely associated with tumour stage and treatment. The treatment-of-first-choice for patients with stage I or II non-small-cell lung cancer is surgical resection [119]. Even for elderly lung cancer patients pulmonary resection is justified, however, a careful preoperative assessment ought to be performed and standard resections should be preferred [120,121].…”

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

“…Some patients with stage IIIa disease will qualify for surgical resection, others should be offered combined radiotherapy and chemotherapy. For most patients with stage IIIb disease, the preferred therapeutic modality is tho-racic radiotherapy in combination with chemotherapy [119]. For patients with stage IV lung cancer, no curative treatment or 'standard therapy' is available [119,122].…”

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

2001

View full text Add to dashboard Cite

show abstract

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

2001

View full text Add to dashboard Cite

show abstract

“…The standard treatment regimen for patients with a traditionally better outcome, those grouped as stage I non-small-cell lung cancer (NSCLC), is resection of the primary tumor without adjuvant therapy. This treatment can cure about twothirds of the patients with stage I disease, although the remaining 30% to 40% of the patients will have tumor recurrence and will die despite complete resection (Bunn et al, 1994;Strauss et al, 1995). Because careful pathologic examination of the primary lesions cannot be used to accurately predict clinical outcome, there exists a great need to identify molecular markers with which to define a subset of stage I NSCLC patients as candidates for new investigational adjuvant therapies, eventually leading to an improvement in patient survival.…”

mentioning

confidence: 99%

Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation

Marchetti

Pellegrini

Buttitta

et al. 2002

Laboratory Investigation

View full text Add to dashboard Cite

SUMMARY:Telomerase activity and telomerase reverse transcriptase (hTERT) expression are elevated in human malignancies.We have investigated telomerase activity measured by the telomeric repeat amplification protocol (TRAP) assay and hTERT levels by real-time RT-PCR in stage I non-small-cell lung carcinomas. The purposes of our study included the comparison of these two techniques in the assessment of telomerase function and the evaluation of their prognostic significance. Telomerase activity and hTERT levels were determined in 90 stage I non-small-cell lung carcinoma patients, using TRAP assay and real-time RT-PCR, respectively. Variables were analyzed by the 2 and Fisher exact tests. Survival was analyzed by the Kaplan-Meier method. Multivariate analysis was performed with the Cox's proportional hazards model. Telomerase activity was elevated in 60 (67%) carcinomas. hTERT was elevated in 43 (48%) carcinomas. Only 21 (23%) tumors had low telomerase function by both TRAP and hTERT expression levels. Telomerase activity and hTERT were significantly correlated (p ϭ 0.017), although 35 cases displayed discordant results. Both telomerase activity and hTERT levels were significantly associated with poor patient overall and disease-free survival (p ϭ 0.019 and p ϭ 0.018 for TRAP, and p ϭ 0.011 and p ϭ 0.012 for hTERT, respectively). Among the 21 patients with tumors displaying low telomerase function, defined by both TRAP and hTERT expression levels, only one succumbed to the disease (p ϭ 0.0053). Our results suggest that the two techniques used in this study evaluate separate aspects of telomerase function and their combination provides powerful prognostic information in lung cancer patients. (Lab Invest 2002, 82:729 -736).

show abstract

“…ESO organises a wide range of clinically oriented educational events including master classes, conferences, advanced courses, seminars, symposia, or workshops [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Euro-Arab School of Oncology: an Educational Collaborative Activity of the European School of Oncology with the Arab World

et al. 2010

View full text Add to dashboard Cite

In this article, we report on the new endeavor of the European School of Oncology to offer collaborative educational activity to the Arab oncologists. We present the 4-year detailed programme held in different Middle East countries with the organization of master classes, advanced courses, or symposia as well as the fellowship programme and the press media events. In addition, we assess the evaluation questionnaires given to the participants during the courses.

show abstract

European School of Oncology First Euro-American Forum on Lung Cancer Treatment

Abstract: The isolation and identification of cis-diammine-chloroplatinum(II)-DNA adducts by anion exchange chromatography and inductively coupled plasma mass spectrometry.

Cited by 18 publications

References 0 publications

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation

Euro-Arab School of Oncology: an Educational Collaborative Activity of the European School of Oncology with the Arab World

Contact Info

Product

Resources

About